Form 4: Ashland SVP Receives Equity Compensation Awards

Ashland's SVP and GM of Life Sciences, Alessandra Faccin, was granted Restricted Stock Units and Stock Appreciation Rights.

Summary

• Alessandra Faccin, SVP and GM of Life Sciences at Ashland Inc., reported changes in beneficial ownership of company securities.
• On November 19, 2025, Ms. Faccin was granted 6,136 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of ASH Common Stock.
• These RSUs will vest in three equal installments, beginning one year from the grant date, contingent on continuous employment.
• Additionally, Ms. Faccin was granted 13,807 Stock Appreciation Rights (SARs) on November 19, 2025.
• The SARs have an exercise price of $50.58 and an expiration date of November 19, 2035.
• SARs become exercisable ratably over three years, starting on the first anniversary of the grant date.
• Both grants were made pursuant to Ashland's shareholder-approved incentive plan and are exempt under Rule 16b-3.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of equity awards to a senior executive is a standard practice to incentivize long-term performance and align management interests with shareholders, which is generally a positive for corporate governance and stability.

Positives

• The grant of equity awards aligns the interests of a senior executive with those of shareholders, incentivizing long-term performance.
• The awards are part of a shareholder-approved incentive plan, indicating good corporate governance.

Future Outlook

The equity grants are designed to incentivize long-term performance and retention of a key executive, suggesting a continued focus on strategic growth within the Life Sciences segment.

Management Comments

• The grants were made pursuant to Ashland's incentive plan as approved by the shareholders and are exempt pursuant to Rule 16b-3.

Industry Context

The granting of equity compensation, such as RSUs and SARs, is a common practice across publicly traded companies, particularly in the specialty chemicals and life sciences sectors, to attract, retain, and motivate senior executives by linking their compensation to company performance and shareholder value.

Comparison to Industry Standards

• The structure of these equity awards, including multi-year vesting schedules and a combination of RSUs and SARs, is consistent with typical executive compensation packages in the specialty chemicals and life sciences industries.
• The use of a Rule 10b5-1(c) plan for the transaction is a standard practice for insiders to manage their equity holdings in compliance with insider trading regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: The compensation structure for senior management can influence overall company culture and employee motivation.

Next Steps

• The Restricted Stock Units will begin vesting in three equal installments starting one year from the grant date (November 19, 2026).
• The Stock Appreciation Rights will become exercisable ratably over three years, beginning on the first anniversary of the grant date (November 19, 2026).

Key Dates

Recommendation

This Form 4 reports a routine grant of equity compensation to a senior executive, which is a standard practice to align management incentives with shareholder interests. It does not provide new information that would significantly alter the investment thesis for Ashland Inc., hence a 'hold' recommendation is appropriate.

Keywords

Ashland Inc., ASH, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU, Stock Appreciation Rights, SAR, Equity Compensation, Executive Compensation, Alessandra Faccin